指南与共识肺结节与肺癌

评估肺癌早期检测的分子生物标志物:生物标志物何时可用于临床?美国胸科学会官方政策声明

Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.
指南 / 共识 · Am J Respir Crit Care Med · 2017-01-01

该政策声明由美国胸科学会成立的项目指导委员会制定,旨在明确支持肺癌早期检测的分子生物标志物用于临床所需的证据水平。声明围绕肺癌筛查和肺结节评估的临床应用,概述了分子生物标志物早期开发阶段应报告的结果类别,讨论了支持临床效用研究的证据水平,描述了判定生物标志物具有临床效用应证明的结局,并建议了能够评估这些结局的研究设计。结论认为分子生物标志物有潜力改善肺癌筛查患者选择和不确定肺结节的特征描述,并提出了判定其是否可用于临床的相关考虑和建议标准。

要点

  • 政策声明明确了肺癌早期检测分子生物标志物用于临床所需的证据水平。
  • 声明围绕肺癌筛查和肺结节评估,概述了生物标志物早期开发应报告的结果类别。
  • 声明建议了评估临床效用结局的研究设计,以判定生物标志物是否可用于临床。

核心结论

  • 分子生物标志物有潜力显著改善肺癌筛查患者的选择和不确定肺结节的特征描述。
  • 声明描述了相关考虑并提出了判定肺癌早期检测分子生物标志物是否可用于临床的标准。

研究设计与样本

  • 美国胸科学会成立了临时项目指导委员会,成员包括来自胸肿瘤学assembly内外、具有肺癌早期检测和分子生物标志物开发专长的个人。
  • 关键问题源自项目指导委员会调查结果,在面对面会议上讨论,讨论结果总结为政策声明,经指导委员会传阅并多次修订以达成共识。

主要发现

  • 政策声明聚焦肺癌筛查和肺结节评估的临床应用,概述了分子生物标志物开发早期阶段应报告的结果类别。
  • 声明讨论了支持临床效用研究的证据水平,描述了判定分子生物标志物具有临床效用应证明的结局,并建议了能够评估这些结局的研究设计。

临床怎么用

  • 在评估肺癌早期检测分子生物标志物是否可用于临床时,可参考该声明提出的证据水平和应证明的结局标准。
  • 该声明可用于指导分子生物标志物在肺癌筛查患者选择和不确定肺结节评估中的临床效用研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular biomarkers have the potential to improve the current state of early lung cancer detection. The goal of this project was to develop a policy statement that provides guidance about the level of evidence required to determine that a molecular biomarker, used to support early lung cancer detection, is appropriate for clinical use. METHODS: An ad hoc project steering committee was formed, to include individuals with expertise in the early detection of lung cancer and molecular biomarker development, from inside and outside of the Assembly on Thoracic Oncology. Key questions, generated from the results of a survey of the project steering committee, were discussed at an in-person meeting. Results of the discussion were summarized in a policy statement that was circulated to the steering committee and revised multiple times to achieve consensus. RESULTS: With a focus on the clinical applications of lung cancer screening and lung nodule evaluation, the policy statement outlines categories of results that should be reported in the early phases of molecular biomarker development, discusses the level of evidence that would support study of the clinical utility, describes the outcomes that should be proven to consider a molecular biomarker clinically useful, and suggests study designs capable of assessing these outcomes. CONCLUSIONS: The application of molecular biomarkers to assist with the early detection of lung cancer has the potential to substantially improve our ability to select patients for lung cancer screening, and to assist with the characterization of indeterminate lung nodules. We have described relevant considerations and have suggested standards to apply when determining whether a molecular biomarker for the early detection of lung cancer is ready for clinical use.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Mazzone PJ, Sears CR, Arenberg DA, et al. Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. Am J Respir Crit Care Med. 2017. PMID: 28960111. doi:10.1164/rccm.201708-1678ST

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。